APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

PDC Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global PDC Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 174022780323 December 2025195 pages

Choose your research edition.

Industry ResearchPDC Drugs Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal PDC Drugs Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal PDC Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal PDC Drugs Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal PDC Drugs Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global PDC Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for PDC Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for PDC Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for PDC Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for PDC Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of PDC Drugs include Bicycle Therapeutics, Cybrexa Therapeutics, Theratechnologies, Beijing Shenogen Pharma Group, BrightGene Bio-Medical Technology, Gaorui Yaoye(Beijing)Technologies, Shanghai Huiyong Pharmaceutical, Shanghai Pharmaceuticals and Lumosa Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global PDC Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of PDC Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents PDC Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the PDC Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

PDC Drugs Segment by Company

Bicycle Therapeutics

Cybrexa Therapeutics

Theratechnologies

Beijing Shenogen Pharma Group

BrightGene Bio-Medical Technology

Gaorui Yaoye(Beijing)Technologies

Shanghai Huiyong Pharmaceutical

Shanghai Pharmaceuticals

Lumosa Therapeutics

Tianjin Conjustar Biotechnology

XINOGEN (HONG KONG) PHARMA

Zhongshan Laibo Ruichen Biopharmaceutical

PDC Drugs Segment by Type

Cell-penetrating Peptides (CPP)

Cell Targeting Peptides (CTP)

Others

PDC Drugs Segment by Application

Breast Cancer

Pancreatic Cancer

Others

PDC Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PDC Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of PDC Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PDC Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the PDC Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of PDC Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of PDC Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of PDC Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. PDC Drugs Industry Trends Table 2. PDC Drugs Industry Drivers Table 3. PDC Drugs Industry Opportunities and Challenges Table 4. PDC Drugs Industry Restraints Table 5. Global PDC Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global PDC Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global PDC Drugs Sales by Manufacturers (k units) & (2021-2026) Table 8. Global PDC Drugs Sales Market Share by Manufacturers Table 9. Global PDC Drugs Average Sales Price (USD/unit) of Manufacturers (2021-2026) Table 10. Global PDC Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global PDC Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global PDC Drugs Manufacturers, Product Type & Application Table 13. Global PDC Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global PDC Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Cell-penetrating Peptides (CPP) Table 17. Major Manufacturers of Cell Targeting Peptides (CTP) Table 18. Major Manufacturers of Others Table 19. Global PDC Drugs Sales by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global PDC Drugs Sales by Type (2021-2026) & (k units) Table 21. Global PDC Drugs Sales by Type (2027-2032) & (k units) Table 22. Global PDC Drugs Sales Market Share by Type (2021-2026) Table 23. Global PDC Drugs Sales Market Share by Type (2027-2032) Table 24. Global PDC Drugs Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 25. Global PDC Drugs Revenue by Type (2021-2026) & (k units) Table 26. Global PDC Drugs Revenue by Type (2027-2032) & (k units) Table 27. Global PDC Drugs Revenue Market Share by Type (2021-2026) Table 28. Global PDC Drugs Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Breast Cancer Table 30. Major Manufacturers of Pancreatic Cancer Table 31. Major Manufacturers of Others Table 32. Global PDC Drugs Sales by Application 2021 VS 2025 VS 2032 (k units) Table 33. Global PDC Drugs Sales by Application (2021-2026) & (k units) Table 34. Global PDC Drugs Sales by Application (2027-2032) & (k units) Table 35. Global PDC Drugs Sales Market Share by Application (2021-2026) Table 36. Global PDC Drugs Sales Market Share by Application (2027-2032) Table 37. Global PDC Drugs Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 38. Global PDC Drugs Revenue by Application (2021-2026) & (k units) Table 39. Global PDC Drugs Revenue by Application (2027-2032) & (k units) Table 40. Global PDC Drugs Revenue Market Share by Application (2021-2026) Table 41. Global PDC Drugs Revenue Market Share by Application (2027-2032) Table 42. Global PDC Drugs Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 43. Global PDC Drugs Sales by Region (2021-2026) & (k units) Table 44. Global PDC Drugs Sales Market Share by Region (2021-2026) Table 45. Global PDC Drugs Sales Forecasted by Region (2027-2032) & (k units) Table 46. Global PDC Drugs Sales Forecasted Market Share by Region (2027-2032) Table 47. North America PDC Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 48. North America PDC Drugs Sales by Country (2021-2026) & (k units) Table 49. North America PDC Drugs Sales by Country (2027-2032) & (k units) Table 50. Europe PDC Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 51. Europe PDC Drugs Sales by Country (2021-2026) & (k units) Table 52. Europe PDC Drugs Sales by Country (2027-2032) & (k units) Table 53. Asia Pacific PDC Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 54. Asia Pacific PDC Drugs Sales by Country (2021-2026) & (k units) Table 55. Asia Pacific PDC Drugs Sales by Country (2027-2032) & (k units) Table 56. South America, Middle East and Africa PDC Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 57. South America, Middle East and Africa PDC Drugs Sales by Country (2021-2026) & (k units) Table 58. South America, Middle East and Africa PDC Drugs Sales by Country (2027-2032) & (k units) Table 59. Global PDC Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global PDC Drugs Revenue by Region (2021-2026) & (US$ Million) Table 61. Global PDC Drugs Revenue by Region (2027-2032) & (US$ Million) Table 62. Global PDC Drugs Revenue Market Share by Region (2021-2026) Table 63. Global PDC Drugs Revenue Market Share by Region (2027-2032) Table 64. Bicycle Therapeutics Company Information Table 65. Bicycle Therapeutics Business Overview Table 66. Bicycle Therapeutics PDC Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Bicycle Therapeutics PDC Drugs Product Portfolio Table 68. Bicycle Therapeutics Recent Development Table 69. Cybrexa Therapeutics Company Information Table 70. Cybrexa Therapeutics Business Overview Table 71. Cybrexa Therapeutics PDC Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Cybrexa Therapeutics PDC Drugs Product Portfolio Table 73. Cybrexa Therapeutics Recent Development Table 74. Theratechnologies Company Information Table 75. Theratechnologies Business Overview Table 76. Theratechnologies PDC Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Theratechnologies PDC Drugs Product Portfolio Table 78. Theratechnologies Recent Development Table 79. Beijing Shenogen Pharma Group Company Information Table 80. Beijing Shenogen Pharma Group Business Overview Table 81. Beijing Shenogen Pharma Group PDC Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Beijing Shenogen Pharma Group PDC Drugs Product Portfolio Table 83. Beijing Shenogen Pharma Group Recent Development Table 84. BrightGene Bio-Medical Technology Company Information Table 85. BrightGene Bio-Medical Technology Business Overview Table 86. BrightGene Bio-Medical Technology PDC Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. BrightGene Bio-Medical Technology PDC Drugs Product Portfolio Table 88. BrightGene Bio-Medical Technology Recent Development Table 89. Gaorui Yaoye(Beijing)Technologies Company Information Table 90. Gaorui Yaoye(Beijing)Technologies Business Overview Table 91. Gaorui Yaoye(Beijing)Technologies PDC Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Gaorui Yaoye(Beijing)Technologies PDC Drugs Product Portfolio Table 93. Gaorui Yaoye(Beijing)Technologies Recent Development Table 94. Shanghai Huiyong Pharmaceutical Company Information Table 95. Shanghai Huiyong Pharmaceutical Business Overview Table 96. Shanghai Huiyong Pharmaceutical PDC Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Shanghai Huiyong Pharmaceutical PDC Drugs Product Portfolio Table 98. Shanghai Huiyong Pharmaceutical Recent Development Table 99. Shanghai Pharmaceuticals Company Information Table 100. Shanghai Pharmaceuticals Business Overview Table 101. Shanghai Pharmaceuticals PDC Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Shanghai Pharmaceuticals PDC Drugs Product Portfolio Table 103. Shanghai Pharmaceuticals Recent Development Table 104. Lumosa Therapeutics Company Information Table 105. Lumosa Therapeutics Business Overview Table 106. Lumosa Therapeutics PDC Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Lumosa Therapeutics PDC Drugs Product Portfolio Table 108. Lumosa Therapeutics Recent Development Table 109. Tianjin Conjustar Biotechnology Company Information Table 110. Tianjin Conjustar Biotechnology Business Overview Table 111. Tianjin Conjustar Biotechnology PDC Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. Tianjin Conjustar Biotechnology PDC Drugs Product Portfolio Table 113. Tianjin Conjustar Biotechnology Recent Development Table 114. XINOGEN (HONG KONG) PHARMA Company Information Table 115. XINOGEN (HONG KONG) PHARMA Business Overview Table 116. XINOGEN (HONG KONG) PHARMA PDC Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 117. XINOGEN (HONG KONG) PHARMA PDC Drugs Product Portfolio Table 118. XINOGEN (HONG KONG) PHARMA Recent Development Table 119. Zhongshan Laibo Ruichen Biopharmaceutical Company Information Table 120. Zhongshan Laibo Ruichen Biopharmaceutical Business Overview Table 121. Zhongshan Laibo Ruichen Biopharmaceutical PDC Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 122. Zhongshan Laibo Ruichen Biopharmaceutical PDC Drugs Product Portfolio Table 123. Zhongshan Laibo Ruichen Biopharmaceutical Recent Development Table 124. Key Raw Materials Table 125. Raw Materials Key Suppliers Table 126. PDC Drugs Distributors List Table 127. PDC Drugs Customers List Table 128. Research Programs/Design for This Report Table 129. Authors List of This Report Table 130. Secondary Sources Table 131. Primary Sources List of Figures Figure 1. PDC Drugs Product Image Figure 2. Global PDC Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global PDC Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global PDC Drugs Sales (2021-2032) & (k units) Figure 5. Global PDC Drugs Average Price (USD/unit) & (2021-2032) Figure 6. Global Top 5 and 10 PDC Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Cell-penetrating Peptides (CPP) Image Figure 9. Cell Targeting Peptides (CTP) Image Figure 10. Others Image Figure 11. Global PDC Drugs Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global PDC Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global PDC Drugs Sales Market Share by Type (2021-2032) Figure 14. Global PDC Drugs Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 15. Global PDC Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global PDC Drugs Revenue Market Share by Type (2021-2032) Figure 17. Breast Cancer Image Figure 18. Pancreatic Cancer Image Figure 19. Others Image Figure 20. Global PDC Drugs Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 21. Global PDC Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global PDC Drugs Sales Market Share by Application (2021-2032) Figure 23. Global PDC Drugs Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 24. Global PDC Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global PDC Drugs Revenue Market Share by Application (2021-2032) Figure 26. North America PDC Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 27. North America PDC Drugs Sales Market Share by Country (2021-2032) Figure 28. U.S. PDC Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 29. Canada PDC Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 30. Mexico PDC Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 31. Europe PDC Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 32. Europe PDC Drugs Sales Market Share by Country (2021-2032) Figure 33. Germany PDC Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 34. France PDC Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 35. U.K. PDC Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 36. Italy PDC Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 37. Netherlands PDC Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 38. Asia Pacific PDC Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 39. Asia Pacific PDC Drugs Sales Market Share by Country (2021-2032) Figure 40. China PDC Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 41. Japan PDC Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 42. South Korea PDC Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 43. Southeast Asia PDC Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 44. India PDC Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 45. Australia PDC Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 46. South America, Middle East and Africa PDC Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 47. South America, Middle East and Africa PDC Drugs Sales Market Share by Country (2021-2032) Figure 48. Brazil PDC Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 49. South Africa PDC Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 50. Saudi Arabia PDC Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 51. Turkey PDC Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 52. Argentina PDC Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 53. UAE PDC Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 54. Egypt PDC Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 55. Chile PDC Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 56. Global PDC Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global PDC Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America PDC Drugs Revenue (2021-2032) & (US$ Million) Figure 59. North America PDC Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe PDC Drugs Revenue (2021-2032) & (US$ Million) Figure 61. Europe PDC Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific PDC Drugs Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific PDC Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa PDC Drugs Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa PDC Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. PDC Drugs Value Chain Figure 67. Manufacturing Cost Structure Figure 68. PDC Drugs Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Cell-penetrating Peptides (CPP)
  • Cell Targeting Peptides (CTP)
  • Others
Applications
  • Breast Cancer
  • Pancreatic Cancer
  • Others
Companies covered
  • Bicycle Therapeutics
  • Cybrexa Therapeutics
  • Theratechnologies
  • Beijing Shenogen Pharma Group
  • BrightGene Bio-Medical Technology
  • Gaorui Yaoye(Beijing)Technologies
  • Shanghai Huiyong Pharmaceutical
  • Shanghai Pharmaceuticals
  • Lumosa Therapeutics
  • Tianjin Conjustar Biotechnology
  • XINOGEN (HONG KONG) PHARMA
  • Zhongshan Laibo Ruichen Biopharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global PDC Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global PDC Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global PDC Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global PDC Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global PDC Drugs Market Dynamics
  1. 2.1 PDC Drugs Industry Trends
  2. 2.2 PDC Drugs Industry Drivers
  3. 2.3 PDC Drugs Industry Opportunities and Challenges
  4. 2.4 PDC Drugs Industry Restraints
3 PDC Drugs Market by Manufacturers
  1. 3.1 Global PDC Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global PDC Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global PDC Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global PDC Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global PDC Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global PDC Drugs Manufacturers, Product Type & Application
  7. 3.7 Global PDC Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global PDC Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 PDC Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 PDC Drugs Tier 1, Tier 2, and Tier 3
4 PDC Drugs Market by Type
  1. 4.1 PDC Drugs Type Introduction
  2. 4.1.1 Cell-penetrating Peptides (CPP)
  3. 4.1.2 Cell Targeting Peptides (CTP)
  4. 4.1.3 Others
  5. 4.2 Global PDC Drugs Sales by Type
  6. 4.2.1 Global PDC Drugs Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global PDC Drugs Sales by Type (2021-2032)
  8. 4.2.3 Global PDC Drugs Sales Market Share by Type (2021-2032)
  9. 4.3 Global PDC Drugs Revenue by Type
  10. 4.3.1 Global PDC Drugs Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global PDC Drugs Revenue by Type (2021-2032)
  12. 4.3.3 Global PDC Drugs Revenue Market Share by Type (2021-2032)
5 PDC Drugs Market by Application
  1. 5.1 PDC Drugs Application Introduction
  2. 5.1.1 Breast Cancer
  3. 5.1.2 Pancreatic Cancer
  4. 5.1.3 Others
  5. 5.2 Global PDC Drugs Sales by Application
  6. 5.2.1 Global PDC Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global PDC Drugs Sales by Application (2021-2032)
  8. 5.2.3 Global PDC Drugs Sales Market Share by Application (2021-2032)
  9. 5.3 Global PDC Drugs Revenue by Application
  10. 5.3.1 Global PDC Drugs Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global PDC Drugs Revenue by Application (2021-2032)
  12. 5.3.3 Global PDC Drugs Revenue Market Share by Application (2021-2032)
6 Global PDC Drugs Sales by Region
  1. 6.1 Global PDC Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global PDC Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global PDC Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global PDC Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America PDC Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America PDC Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe PDC Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe PDC Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific PDC Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific PDC Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa PDC Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa PDC Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global PDC Drugs Revenue by Region
  1. 7.1 Global PDC Drugs Revenue by Region
  2. 7.1.1 Global PDC Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global PDC Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global PDC Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global PDC Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America PDC Drugs Revenue (2021-2032)
  8. 7.2.2 North America PDC Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe PDC Drugs Revenue (2021-2032)
  11. 7.3.2 Europe PDC Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific PDC Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific PDC Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa PDC Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa PDC Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Bicycle Therapeutics
  2. 8.1.1 Bicycle Therapeutics Company Information
  3. 8.1.2 Bicycle Therapeutics Business Overview
  4. 8.1.3 Bicycle Therapeutics PDC Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Bicycle Therapeutics PDC Drugs Product Portfolio
  6. 8.1.5 Bicycle Therapeutics Recent Developments
  7. 8.2 Cybrexa Therapeutics
  8. 8.2.1 Cybrexa Therapeutics Company Information
  9. 8.2.2 Cybrexa Therapeutics Business Overview
  10. 8.2.3 Cybrexa Therapeutics PDC Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Cybrexa Therapeutics PDC Drugs Product Portfolio
  12. 8.2.5 Cybrexa Therapeutics Recent Developments
  13. 8.3 Theratechnologies
  14. 8.3.1 Theratechnologies Company Information
  15. 8.3.2 Theratechnologies Business Overview
  16. 8.3.3 Theratechnologies PDC Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Theratechnologies PDC Drugs Product Portfolio
  18. 8.3.5 Theratechnologies Recent Developments
  19. 8.4 Beijing Shenogen Pharma Group
  20. 8.4.1 Beijing Shenogen Pharma Group Company Information
  21. 8.4.2 Beijing Shenogen Pharma Group Business Overview
  22. 8.4.3 Beijing Shenogen Pharma Group PDC Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Beijing Shenogen Pharma Group PDC Drugs Product Portfolio
  24. 8.4.5 Beijing Shenogen Pharma Group Recent Developments
  25. 8.5 BrightGene Bio-Medical Technology
  26. 8.5.1 BrightGene Bio-Medical Technology Company Information
  27. 8.5.2 BrightGene Bio-Medical Technology Business Overview
  28. 8.5.3 BrightGene Bio-Medical Technology PDC Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 BrightGene Bio-Medical Technology PDC Drugs Product Portfolio
  30. 8.5.5 BrightGene Bio-Medical Technology Recent Developments
  31. 8.6 Gaorui Yaoye(Beijing)Technologies
  32. 8.6.1 Gaorui Yaoye(Beijing)Technologies Company Information
  33. 8.6.2 Gaorui Yaoye(Beijing)Technologies Business Overview
  34. 8.6.3 Gaorui Yaoye(Beijing)Technologies PDC Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Gaorui Yaoye(Beijing)Technologies PDC Drugs Product Portfolio
  36. 8.6.5 Gaorui Yaoye(Beijing)Technologies Recent Developments
  37. 8.7 Shanghai Huiyong Pharmaceutical
  38. 8.7.1 Shanghai Huiyong Pharmaceutical Company Information
  39. 8.7.2 Shanghai Huiyong Pharmaceutical Business Overview
  40. 8.7.3 Shanghai Huiyong Pharmaceutical PDC Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Shanghai Huiyong Pharmaceutical PDC Drugs Product Portfolio
  42. 8.7.5 Shanghai Huiyong Pharmaceutical Recent Developments
  43. 8.8 Shanghai Pharmaceuticals
  44. 8.8.1 Shanghai Pharmaceuticals Company Information
  45. 8.8.2 Shanghai Pharmaceuticals Business Overview
  46. 8.8.3 Shanghai Pharmaceuticals PDC Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Shanghai Pharmaceuticals PDC Drugs Product Portfolio
  48. 8.8.5 Shanghai Pharmaceuticals Recent Developments
  49. 8.9 Lumosa Therapeutics
  50. 8.9.1 Lumosa Therapeutics Company Information
  51. 8.9.2 Lumosa Therapeutics Business Overview
  52. 8.9.3 Lumosa Therapeutics PDC Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Lumosa Therapeutics PDC Drugs Product Portfolio
  54. 8.9.5 Lumosa Therapeutics Recent Developments
  55. 8.10 Tianjin Conjustar Biotechnology
  56. 8.10.1 Tianjin Conjustar Biotechnology Company Information
  57. 8.10.2 Tianjin Conjustar Biotechnology Business Overview
  58. 8.10.3 Tianjin Conjustar Biotechnology PDC Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Tianjin Conjustar Biotechnology PDC Drugs Product Portfolio
  60. 8.10.5 Tianjin Conjustar Biotechnology Recent Developments
  61. 8.11 XINOGEN (HONG KONG) PHARMA
  62. 8.11.1 XINOGEN (HONG KONG) PHARMA Company Information
  63. 8.11.2 XINOGEN (HONG KONG) PHARMA Business Overview
  64. 8.11.3 XINOGEN (HONG KONG) PHARMA PDC Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 XINOGEN (HONG KONG) PHARMA PDC Drugs Product Portfolio
  66. 8.11.5 XINOGEN (HONG KONG) PHARMA Recent Developments
  67. 8.12 Zhongshan Laibo Ruichen Biopharmaceutical
  68. 8.12.1 Zhongshan Laibo Ruichen Biopharmaceutical Company Information
  69. 8.12.2 Zhongshan Laibo Ruichen Biopharmaceutical Business Overview
  70. 8.12.3 Zhongshan Laibo Ruichen Biopharmaceutical PDC Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Zhongshan Laibo Ruichen Biopharmaceutical PDC Drugs Product Portfolio
  72. 8.12.5 Zhongshan Laibo Ruichen Biopharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 PDC Drugs Value Chain Analysis
  2. 9.1.1 PDC Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 PDC Drugs Production Mode & Process
  6. 9.2 PDC Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 PDC Drugs Distributors
  9. 9.2.3 PDC Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst